Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 1/20 | 0.61 |
| ▸ | TP53 | P04637 | 2/20 | 0.61 |
| ▸ | MAPT | P10636 | 2/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.60 |
| ▸ | HPGD | P15428 | 1/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | MAOB | P27338 | 6/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.57 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.53 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.52 |
| ▸ | MAOA | P21397 | 3/20 | 0.51 |
| ▸ | CA12 | O43570 | 1/20 | 0.51 |
| ▸ | CA1 | P00915 | 1/20 | 0.51 |
| ▸ | CA2 | P00918 | 1/20 | 0.51 |
| ▸ | CA3 | P07451 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1367003 | 0.80 | GPR35 (0.79) | MAPTALDH1A1HPGDMAOBGPR35 | |
| SCHEMBL1369613 | 0.78 | MAPT (0.74) | MAPTALDH1A1HPGDMEN1CYP1A2 | |
| SCHEMBL830715 | 0.77 | TP53 (0.79) | PIM1TP53MAPTALDH1A1HPGD | |
| SCHEMBL7382658 | 0.76 | PIM1 (1.00) | PIM1TP53MAPTALDH1A1MEN1 | |
| SCHEMBL7380636 | 0.76 | PIM1 (0.78) | PIM1TP53MAPTALDH1A1HPGD | |
| SCHEMBL28807108 | 0.74 | GPR35 (0.60) | PIM1TP53MAPTALDH1A1MAOB | |
| SCHEMBL28805354 | 0.73 | CNR2 (0.66) | TP53MAPTALDH1A1MAOBGPR35 | |
| SCHEMBL13810951 | 0.73 | PIM1 (0.59) | PIM1TP53MAPTALDH1A1HPGD | |
| SCHEMBL16708178 | 0.72 | PIM1 (0.72) | PIM1TP53MAPTALDH1A1HPGD | |
| SCHEMBL1368772 | 0.72 | CA12 (0.47) | MAPTALDH1A1HPGDMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090275650-A1 | 3-Acyl coumarins, thiochromones and quinolones and therapeutic uses thereof | TEMPLE UNIVERSITY- OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2009-11-05 | — | — | US | claimed |
| US-8067461-B2 | 3-acyl coumarins, thiochromones and quinolones and therapeutic uses thereof | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2011-11-29 | — | — | US | disclosed |
| US-20090275650-A1 | 3-Acyl coumarins, thiochromones and quinolones and therapeutic uses thereof | TEMPLE UNIVERSITY- OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2009-11-05 | — | — | US | disclosed |
| WO-2006132947-A2 | 3-ACYL COUMARINS, THIOCHROMONES AND QUINOLONES AND THERAPEUTIC USES THEREOF | TEMPLE UNIVERSITY- OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2006-12-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275650-A1 | 3-Acyl coumarins, thiochromones and quinolones and therapeutic uses thereof | NQO2, NQO1, HCCS | PIM1 1647/4885TP53 142/4885MAPT 4718/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.